Researchers at Weill Cornell Medicine have developed Cyclone, an innovative gene-switch technology that enables precise and non-toxic control over gene activity. This advancement could significantly impact biomedical research and gene therapy development, providing a safer alternative to existing methods.
Cyclone, detailed in a recent paper in Nature Methods, employs a modified “poison exon” to suppress gene activity. This engineered exon, inserted into any target gene, can be deactivated with the antiviral drug acyclovir, allowing gene expression to resume. Unlike other gene-switch tools, Cyclone’s use of acyclovir avoids the toxic effects associated with drugs like tetracycline, maintaining the integrity of RNA transcripts and proteins.
Dr. Samie Jaffrey, senior author and the Greenberg-Starr Professor at Weill Cornell Medicine, stated, “We think the Cyclone concept has great potential for diverse applications requiring the safe and precise control of gene activity.”
The Cyclone system can increase gene activity from nearly 0% to over 300% of normal levels, depending on the acyclovir dosage. It is versatile, functioning with both artificial and natural genes, and has potential for simultaneous manipulation of multiple genes using different Cyclone-type systems. This capability suggests a future role in gene therapies as a reversible safety mechanism to regulate therapeutic gene activity.
For further details, refer to the original study in Nature Methods: A portable poison exon for small-molecule control of mammalian gene expression.
